Therefore, the number of patients in this study is limited to 42, and evaluation of CD86-low status as a predictive biomarker requires a follow-up validation study, with a planned number of patients determined using the Reporting Recommendations for Tumor Marker Prognostic Studies guidelines. The gene discussed is CD86; the disease is neoplasm.